Takeda Pharmaceutical Co (BSP:TAKP34) Moat Score: 7/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:TAKP34 Takeda Pharmaceutical Co Ltd BSP:TAKP34
64 GF Score
Price R$82.32
GF Value R$70.13
! 9 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Moat Score?

Takeda Pharmaceutical Co BSP:TAKP34 64 Moat Score is 7 as of Jul. 15, 2026. GuruFocus rates BSP:TAKP34 with a GF Score™ of 64/100 and a GF Value™ of R$70.13. The stock has 9 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Takeda Pharmaceutical Co ranks better than 98.64% on this metric.

Takeda Pharmaceutical Co has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Takeda Pharmaceutical Co has Wide Moat: Takeda Pharmaceutical Co Ltd has a wide moat due to its strong portfolio of patents, significant R&D capabilities, and established brand in the pharmaceutical industry, providing durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Takeda Pharmaceutical Co might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Takeda Pharmaceutical Co  (BSP:TAKP34) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Takeda Pharmaceutical Co Moat Score Related Terms

BSP:TAKP34 vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takeda Pharmaceutical Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Moat Score falls into.


BSP:TAKP34
64GF Score
Takeda Pharmaceutical Co Ltd BSP:TAKP34
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Takeda Pharmaceutical Co (BSP:TAKP34) has a Moat Score of 7 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #14 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Takeda Pharmaceutical Co's Moat Score too high?
Takeda Pharmaceutical Co's current Moat Score is 7. Based on the distribution chart, Takeda Pharmaceutical Co ranks #14 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Takeda Pharmaceutical Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #14 out of 1031 companies for Moat Score. This places Takeda Pharmaceutical Co in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Takeda Pharmaceutical Co's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Takeda Pharmaceutical Co (BSP:TAKP34) has a current Moat Score of 7. The stock's GF Value™ is R$70.13, compared to a current price of R$82.32 — trading 17.4% above its estimated fair value. The current Moat Score is 7. Takeda Pharmaceutical Co's overall GF Score™ is 64/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Takeda Pharmaceutical Co (BSP:TAKP34), the current Moat Score is 7 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (BSP:TAKP34) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of R$82.32 is trading 17.4% above its estimated GF Value™ of R$70.13.

Key valuation signals for BSP:TAKP34:

  • Moat Score: 7
  • GF Value™: R$70.13 vs. price of R$82.32 (17.4% above fair value)
  • GF Score™: 64/100 with 9 warning signs

No single metric tells the full story. See the BSP:TAKP34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
64GF Score

Get the complete analysis for BSP:TAKP34

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$82.32
Price
R$70.13
GF Value